« Back to Record
Citation APA

de Azambuja, E., Agostinetto, E., Procter, M., Eiger, D., Pondé, N., Guillaume, S., Parlier, D., Lambertini, M., Desmet, A., Caballero, C., Aguila, C., Jerusalem, G., Walshe, J. M., Frank, E. E., Bines, J., Loibl, S., Piccart-Gebhart, M., Ewer, M., Dent, S., Plummer, C. J. C., & Suter, T. (2023). Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO Open, 8(1), 100772. doi:10.1016/j.esmoop.2022.100772


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/372023

de Azambuja, E., Agostinetto, E., Procter, M., Eiger, D., Pondé, N., Guillaume, S., Parlier, D., Lambertini, M., Desmet, A., Caballero, C., Aguila, C., Jerusalem, G., Walshe, J. M., Frank, E. E., Bines, J., Loibl, S., Piccart-Gebhart, M., Ewer, M., Dent, S., Plummer, C. J. C., & Suter, T. (2023). Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO Open, 8(1), 100772. doi:10.1016/j.esmoop.2022.100772